Navigation Links
Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years
Date:9/25/2011

ndocrine therapies. While long-term safety data are available for tamoxifen, follow-up of patients who have received letrozole or other aromatase inhibitors is still relatively short. Thus, assessment of the long-term safety of letrozole is a critical objective for the BIG 1-98 follow-up study."

The IBCSG recently launched a long-term observational study that will extend patient follow-up for an additional five years in order to provide further information on efficacy and side effects of five years of adjuvant hormone therapy. "The follow-up study includes collection of yearly updates of survival, disease status and long-term adverse events. We plan to continue to update results every two years. This study is critically important as more than 74% of the patients enrolled in BIG 1-98 were still alive without a relapse at their most recent study visit. Assessment especially of long-term side effects for these patients is critically important," he said.

"BIG 1-98 and other large randomised clinical trials have firmly established the benefits of adjuvant treatment programmes including aromatase inhibitors, such as letrozole. Improved disease control and extended survival will reduce burdens on healthcare systems by reducing the number of patients requiring treatment for metastatic breast cancer. Furthermore, the cost of aromatase inhibitor treatment will decrease in the near future as generic products become available," Prof Gelber added.

Professor Michael Baumann, president of ECCO said: "This 12-year update of the study sheds more light on the advantages of aromatase inhibitors over tamoxifen in the adjuvant treatment of early breast cancer. It also clearly demonstrates how important it is to perform long-term follow-up and analysis of clinical studies especially for breast cancer. Long-term analysis is essential for reliably ensuring the efficacy of treatments but also to detect potential long-term side-effects which may affect quality of
'/>"/>

Contact: Kay Roche
kayroche@gmail.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Study sheds light on aromatase inhibitor joint pain syndrome
2. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
3. Patients Who Take a Proton-Pump Inhibitor With Medicine to Prevent Blood Clots Are Less Likely to Be Hospitalized for Bleeding Ulcers
4. BRAF inhibitor shows promising preclinical activity against melanoma
5. JAK inhibitor provides rapid, durable relief for myelofibrosis patients
6. Novel biomarker may predict response to new VEGF receptor inhibitor
7. Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
8. PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans
9. JAK inhibitors producing significant response in myelofibrosis patients
10. Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate
11. Combining 2 peptide inhibitors might block tumor growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a ... Patient Education content is ICD-10 ready and available to all clients. All Krames ... code sets, which are more targeted and return a more comprehensive data set ...
(Date:8/27/2015)... ... 27, 2015 , ... Banc Intranets recently entered into a strategic ... both Johnson City, Tenn.-based firms to work synergistically to promote similar products to the ... caters to organizations in the financial, commercial and services sectors. The software, which is ...
(Date:8/27/2015)... ... 2015 , ... Susan Harris and the team at LifeStream Health ... pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch is ... the vaginal tissue, revitalizing cells so they make more collagen, an essential component in ...
(Date:8/27/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and Innovation, ... Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , Ms. ...
(Date:8/27/2015)... ... 2015 , ... Standifer Insurance Group, a full service insurance ... joint charity drive with the Meadow View Elementary School in Alabaster. , A ... many lack the simple supplies necessary for a productive scholastic career. In partnering ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 3
... people seeking active participation in their communities has led researchers to ... engagement can now be considered a distinct retirement role, according to ... (Volume 48, Number 3). , The authors ... at least one day per week that directly impact the ...
... hours for participants in phase II trial , , ... drug called pegloticase lowered levels of uric acid in ... in most patients. , That,s the conclusion of a ... Savient Pharmaceuticals, the company that,s developing the drug. ...
... Trim Holdings,Inc. (Amex: ZTM ) announced today ... private placement subscription agreements pursuant to which we,sold ... for an,aggregate offering price of $2,370,000. Each of ... consists of a $100,000 24-month,senior secured promissory note ...
... overwhelmingly positive, PORTLAND, Ore., Sept. 3 ... doctor to others, according to a,popular online survey ... A,"Member Feedback" feature on the site allows Regence ... providers, including,physicians, dentists, other health care professionals and ...
... Amsterdam, September 3, 2008 A recent study (doi:10.1016/j.clim.2008.06.009) ... of the Clinical Immunology Society (CIS), describes a new ... human cells. The report demonstrates the characterization of specific ... providing information about the role these cells might play ...
... new survey by Medical Economics details surprising statistics on earnings and ... in wages for many doctors accompanied by a decrease in patient ... ... 2008 -- A newly-released 2008 Medical Economics survey focusing on earnings ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
(Date:8/27/2015)... CardioVascular Institute enrolled the first patient in Pennsylvania ... in a trial assessing the safety and effectiveness ... main artery of the leg. The new stent allows for ... stent fracture or re-narrowing after the stent is placed. ... the BioMimics 3D Stent System and will enroll 280 subjects ...
(Date:8/27/2015)...  Lightwave Logic, Inc. (OTCQB: LWLG), a technology ... Generation Photonic Devices and Non-Linear Optical Polymer Materials ... data communications and optical computing, announced today that ... to the Company,s Board of Directors. ... is widely recognized with wide-ranging experience across many ...
(Date:8/27/2015)... SAN FRANCISCO, Calif. , Aug. 27, 2015 ... Probody™ therapeutics for the treatment of cancer, today ... a member of the company,s Board of Directors, ... formerly led immuno-oncology at Eli Lilly and AstraZeneca, ... the first FDA approved checkpoint inhibitor, at Bristol-Myers ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... May 7, 2012  AssureRx Health, Inc. today announced ... the growing number of children and adults diagnosed ... pharmacogenomic test can assist clinicians with important medication ... individual patients tolerate ADHD medications. ...
...  BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, ... announced the completion of a randomized, controlled trial ... product.  ActiPatch uses pulsed electromagnetic field therapy to ... injured tissue. A double blind, ...
Cached Medicine Technology:AssureRx Health Launches Personalized Medicine Test for ADHD 2AssureRx Health Launches Personalized Medicine Test for ADHD 3BioElectronics' ActiPatch Reduces Muscle Soreness in Runners 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: